Evidence map›Paper›PMID 33215562›Full record

Trial reportJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners2021

Glasdegib plus low-dose cytarabine for acute myeloid leukemia: Practical considerations from advanced practitioners and pharmacists.

Valerie Relias, Ali McBride, Matthew J Newman, Shilpa Paul, Seyyedeh Saneeymehri, Genique Stanislaus, Jennifer Tobin, Caroline J Hoang, Joanne C Ryan, Ilene Galinsky

Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 1 country.

Valerie ReliasDivision of Hematology/Oncology, Tufts Medical Center, Boston, MA, USA.ORCID https://orcid.org/0000-0002-1476-5747
Ali McBrideDepartment of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ, USA.
Matthew J NewmanThe Johns Hopkins Hospital Department of Pharmacy, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-1402-5554
Shilpa PaulDepartment of Pharmacy at the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Seyyedeh SaneeymehriEmory University Hospital/Winship Cancer Institute, Atlanta, GA, USA.
Genique StanislausJohn Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Jennifer TobinBlood Disorders Center, University of Colorado Hospital, Aurora, CO, USA.
Caroline J HoangPfizer Oncology, Pfizer Inc., New York, NY, USA.
Joanne C RyanPfizer Oncology, Pfizer Inc., New York, NY, USA.
Ilene GalinskyDepartment of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA.
Pfizer (United States) · USDana-Farber Cancer Institute · USEmory University Hospital · USHackensack University Medical Center · USJohns Hopkins Hospital · USThe University of Texas MD Anderson Cancer Center · USTufts Medical Center · USUniversity of Arizona · USUniversity of Colorado Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAcute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in combination with low-dose cytarabine (LDAC).

conclusionsPharmacists and advanced practitioners play important roles in treatment with glasdegib plus LDAC. Ultimately, framing plans for treatment delivery within the individual circumstances of each patient may enable them to stay on therapy longer, giving them the greatest potential to achieve benefit.

Indexed as

AgedAged, 80 and overAntimetabolites, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesCytarabineDrug InteractionsFemaleGastrointestinal DiseasesHematologic DiseasesHumansLeukemia, Myeloid, AcuteMalePharmacistsPhenylurea CompoundsPhysiciansAntimetabolites, AntineoplasticBenzimidazolesCytarabineglasdegibPhenylurea CompoundsAcute myeloid leukemiaelderlyglasdegibhedgehog pathway inhibitorlow-dose cytarabine

Identifiers

PMID33215562
PMCPMC8008421
OpenAlexW3097996957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.